GMED

Globus Medical

GMED, USA

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip and knee joint solutions, including modular hip stems and acetabular cups for total hip arthroplasty, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants; and neuromonitoring services, which provides onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also offers enabling technologies, such as imaging, navigation, and robotics (INR) solutions for assisted surgery, which includes the ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures with screw and interbody spacer placement applications; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative, image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

https://www.globusmedical.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GMED
stock
GMED

Globus Medical (GMED) Valuation Check After Updated Guidance And NuVasive Synergy Outlook simplywall.st

Read more →
GMED
stock
GMED

Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report? Finviz

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$98.7273

Analyst Picks

Strong Buy

4

Buy

5

Hold

5

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Medium

28.25

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

2.94

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

2.70 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

2.33 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

28.46 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.16

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 72.47% of the total shares of Globus Medical

1.

BlackRock Inc

(7.9696%)

since

2025/06/30

2.

Vanguard Group Inc

(7.9292%)

since

2025/06/30

3.

HHG PLC

(6.0766%)

since

2025/06/30

4.

iShares Core S&P Mid-Cap ETF

(2.7222%)

since

2025/08/31

5.

Vanguard Total Stock Mkt Idx Inv

(2.6306%)

since

2025/07/31

6.

Burgundy Asset Management Ltd

(2.5777%)

since

2025/06/30

7.

State Street Corp

(2.5718%)

since

2025/06/30

8.

JPMorgan Chase & Co

(2.4736%)

since

2025/06/30

9.

OZ Management LLC

(2.0441%)

since

2025/06/30

10.

Vanguard Small Cap Index

(2.0306%)

since

2025/07/31

11.

William Blair Investment Management, LLC

(1.7807%)

since

2025/06/30

12.

Hawk Ridge Management LLC

(1.5721%)

since

2025/06/30

13.

Vanguard Explorer Inv

(1.5443%)

since

2025/06/30

14.

Geneva Capital Management

(1.5422%)

since

2025/06/30

15.

JPMorgan Mid Cap Value L

(1.5096%)

since

2025/07/31

16.

JPM US Mid Cap Value-Composite

(1.498%)

since

2025/06/30

17.

Geode Capital Management, LLC

(1.4759%)

since

2025/06/30

18.

Wellington Management Company LLP

(1.4576%)

since

2025/06/30

19.

GW&K Investment Management, LLC

(1.3696%)

since

2025/06/30

20.

Janus Inst Mid Cap Growth CF

(1.2863%)

since

2025/06/30

21.

Janus Henderson Enterprise D

(1.2863%)

since

2025/06/30

22.

Madison Avenue Partners, LP

(1.2677%)

since

2025/06/30

23.

Marshall Wace Asset Management Ltd

(1.1702%)

since

2025/06/30

24.

Vanguard Small Cap Growth Index Inv

(1.1439%)

since

2025/07/31

25.

AXA SA

(1.1318%)

since

2025/06/30

26.

Manufacturers Life Insurance Co

(1.0874%)

since

2025/06/30

27.

Janus Henderson US Opportunistic Alpha

(1.0534%)

since

2025/06/30

28.

Janus Henderson Contrarian D

(1.0534%)

since

2025/06/30

29.

Van Berkom and Associates Inc

(0.9509%)

since

2025/06/30

30.

Janus Henderson Triton D

(0.9043%)

since

2025/06/30

31.

Janus Henderson US SMID Cap Growth MA

(0.9043%)

since

2025/06/30

32.

Janus Henderson US SMID Cap Growth

(0.9043%)

since

2025/06/30

33.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8992%)

since

2025/07/31

34.

Charles Schwab Investment Management Inc

(0.8729%)

since

2025/06/30

35.

Dimensional Fund Advisors, Inc.

(0.8652%)

since

2025/06/30

36.

Champlain Small Company Fund, LLC

(0.6425%)

since

2025/08/31

37.

SPDR® S&P MIDCAP 400 ETF Trust

(0.6406%)

since

2025/07/31

38.

T. Rowe Price Integrated US Sm Gr Eq

(0.5542%)

since

2025/07/31

39.

T. Rowe Price Integrated US SmCapGrEq

(0.5542%)

since

2025/06/30

40.

Invesco S&P MidCap Momentum ETF

(0.5232%)

since

2025/08/29

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

1.18

EPS Estimate

0.77

EPS Difference

0.41

Surprise Percent

53.2468%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(8.3)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4)
Net Net
Possible Net-Net(4)
Quality
High Quality(8)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.